Skip to main content
SpringerLink
Log in

ARTEMIS will assess impact of no copayment on MI costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. composite of all-cause death, recurrent MI and stroke

Reference

  • Doll JA, et al. Rationale and design of the Affordability and Real-world Antiplatelet Treatment Effectiveness after Myocardial Infarction Study (ARTEMIS): A multicenter, cluster-randomized trial of P2Y12 receptor inhibitor copayment reduction after myocardial infarction. American Heart Journal 177: 33-41, Jul 2016. Available from: URL: http://doi.org/10.1016/j.ahj.2016.04.008

    Article  CAS  PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

ARTEMIS will assess impact of no copayment on MI costs. PharmacoEcon Outcomes News 756, 11 (2016). https://doi.org/10.1007/s40274-016-3160-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3160-8

Search

Navigation